Medifast (MED) Expected to Release Quarterly Earnings on Monday

Key Points

• Medifast is expected to report Q3 2026 results after Monday’s market close, with analysts forecasting a loss of $0.35 per share and revenue of $71.30 million. The earnings conference call is scheduled for October 26 at 8:30 a.m. ET.
• The company’s latest quarter exceeded expectations, reporting a $0.28-per-share loss versus the projected $0.65 loss and revenue of $76.38 million versus the $72.70 million estimate. Analysts expect full-year EPS of negative $1.04.
• Medifast shares recently traded near $11.89, while the analyst consensus rating remains Hold with a $12.00 price target. Insider activity has been mixed, including a director’s sale of 9,544 shares and another director’s purchase of 43,150 shares.

Medifast (NYSE:MED - Get Free Report) is expected to announce its Q3 2026 results after the market closes on Monday, October 26th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $71.30 million for the quarter. Medifast has set its FY 2026 guidance at -1.750--0.250 EPS and its Q3 2026 guidance at -0.650--0.150 EPS. Parties can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, October 26, 2026 at 8:30 AM ET.

Medifast (NYSE:MED - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.37. The firm had revenue of $76.38 million during the quarter, compared to analysts' expectations of $72.70 million. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%. On average, analysts expect Medifast to post ($1.04) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Medifast Trading Up 0.1%

Shares of Medifast stock opened at $11.89 on Monday. The firm has a market capitalization of $132.94 million, a PE ratio of -5.10 and a beta of 0.68. The business's 50-day moving average price is $11.91 and its 200-day moving average price is $11.49. Medifast has a 12 month low of $9.22 and a 12 month high of $13.58.

Insider Activity

In other news, Director Daniel R. Chard sold 9,544 shares of Medifast stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $11.73, for a total value of $111,951.12. Following the transaction, the director owned 130,609 shares in the company, valued at approximately $1,532,043.57. The trade was a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Parsa Kiai bought 43,150 shares of the stock in a transaction dated Wednesday, August 26th. The stock was bought at an average cost of $12.26 per share, with a total value of $529,019.00. Following the purchase, the director owned 707,492 shares in the company, valued at $8,673,851.92. The trade was a 6.50% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 119,966 shares of company stock valued at $1,423,576. Company insiders own 3.70% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Weiss Ratings raised Medifast from a "sell (e+)" rating to a "sell (d)" rating in a research note on Monday, August 17th. Zacks Research raised shares of Medifast from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $12.00.

Medifast Company Profile

Medifast, Inc is a health and wellness company that provides weight-management and healthy-living products and services. Its primary brand, OPTAVIA, offers meal replacements, snacks, supplements and other nutrition products designed to support structured weight-management programs.

The company's programs combine nutrition products with guidance from independent OPTAVIA Coaches. These coaches provide accountability, support and lifestyle guidance intended to help clients develop healthier eating and activity habits.

Medifast was founded in 1980 and is headquartered in Baltimore, Maryland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.